ECSP19078277A - Nuevos ligadores peptídicos y conjugados de criptoficina y su preparación - Google Patents
Nuevos ligadores peptídicos y conjugados de criptoficina y su preparaciónInfo
- Publication number
- ECSP19078277A ECSP19078277A ECSENADI201978277A ECDI201978277A ECSP19078277A EC SP19078277 A ECSP19078277 A EC SP19078277A EC SENADI201978277 A ECSENADI201978277 A EC SENADI201978277A EC DI201978277 A ECDI201978277 A EC DI201978277A EC SP19078277 A ECSP19078277 A EC SP19078277A
- Authority
- EC
- Ecuador
- Prior art keywords
- conjugates
- cryptophyphin
- preparation
- disclosure
- chemical group
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title 1
- 229930188224 Cryptophycin Natural products 0.000 abstract 2
- 125000003636 chemical group Chemical group 0.000 abstract 2
- 108010006226 cryptophycin Proteins 0.000 abstract 2
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 abstract 2
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305531 | 2017-05-10 | ||
| PCT/EP2018/061989 WO2018206635A1 (en) | 2017-05-10 | 2018-05-09 | Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19078277A true ECSP19078277A (es) | 2019-11-30 |
Family
ID=58873750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201978277A ECSP19078277A (es) | 2017-05-10 | 2019-10-31 | Nuevos ligadores peptídicos y conjugados de criptoficina y su preparación |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US20180369401A1 (https=) |
| EP (1) | EP3621658A1 (https=) |
| JP (2) | JP2020519610A (https=) |
| KR (1) | KR102722886B1 (https=) |
| CN (1) | CN110831633A (https=) |
| AR (1) | AR111781A1 (https=) |
| AU (2) | AU2018265333C1 (https=) |
| BR (1) | BR112019023336A2 (https=) |
| CA (1) | CA3062977A1 (https=) |
| CO (1) | CO2019012108A2 (https=) |
| EA (1) | EA201992667A1 (https=) |
| EC (1) | ECSP19078277A (https=) |
| IL (1) | IL270507B2 (https=) |
| MA (1) | MA50764A (https=) |
| MX (1) | MX2019013421A (https=) |
| MY (1) | MY204075A (https=) |
| PH (1) | PH12019550230A1 (https=) |
| TN (1) | TN2019000303A1 (https=) |
| TW (1) | TWI778059B (https=) |
| UY (1) | UY37728A (https=) |
| WO (1) | WO2018206635A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| ES3024474T3 (en) | 2016-12-30 | 2025-06-04 | Vaxcyte Inc | Polypeptide-antigen conjugates with non-natural amino acids |
| EP3621658A1 (en) | 2017-05-10 | 2020-03-18 | Sanofi | Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation |
| CN111154133B (zh) * | 2020-01-03 | 2022-07-12 | 万华化学集团股份有限公司 | 一种环氧树脂发泡剂，环氧树脂组合物及环氧发泡材料的制备方法和用途 |
| CN114053426B (zh) * | 2020-07-30 | 2024-06-18 | 成都科岭源医药技术有限公司 | 一种双药链接组装单元及双药靶向接头-药物偶联物 |
| CN115105607B (zh) * | 2021-03-22 | 2024-12-20 | 成都科岭源医药技术有限公司 | 一种用于adc的双药-接头的制备方法及其用途 |
| KR20240150807A (ko) | 2022-02-22 | 2024-10-16 | 아라리스 바이오테크 아게 | 2개 이상의 페이로드를 포함하는 펩티드 링커 |
| CN115212315A (zh) * | 2022-08-03 | 2022-10-21 | 联宁（苏州）生物制药有限公司 | 一种抗体偶联药物中间体及含有其的抗体偶联药物 |
| WO2025082990A1 (en) | 2023-10-15 | 2025-04-24 | Araris Biotech Ag | Antibody-drug conjugates using two different types of topoisomerase i inhibitors |
| WO2026013234A1 (en) | 2024-07-10 | 2026-01-15 | Araris Biotech Ag | Triple-payload antibody-drug conjugates (adcs) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4040907A (en) * | 1974-06-20 | 1977-08-09 | Syva Company | Iodothyronine enzyme conjugates |
| WO1995017093A1 (en) | 1993-12-21 | 1995-06-29 | University Of Hawaii | New cryptophycins |
| PT934065E (pt) * | 1996-08-30 | 2006-10-31 | Univ Hawaii | Compostos farmaceuticos |
| US20020128185A1 (en) | 1998-02-25 | 2002-09-12 | Chuan Shih | Pharmaceutical compounds |
| US7230101B1 (en) | 2002-08-28 | 2007-06-12 | Gpc Biotech, Inc. | Synthesis of methotrexate-containing heterodimeric molecules |
| US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
| EP2010475A2 (en) | 2006-04-27 | 2009-01-07 | Intezyne Technologies Incorporated | Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof |
| ES2673822T3 (es) | 2006-07-18 | 2018-06-25 | Sanofi | Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer |
| BRPI0812970A2 (pt) * | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
| FR2947269B1 (fr) * | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| US8953557B2 (en) | 2009-06-30 | 2015-02-10 | Alcatel Lucent | Roaming method for a mobile terminal in WLAN, related access controller and access point device |
| TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
| WO2015057876A1 (en) * | 2013-10-15 | 2015-04-23 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| ES2826398T3 (es) | 2013-10-15 | 2021-05-18 | Seagen Inc | Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco |
| EP3068443B1 (en) * | 2013-11-12 | 2019-04-10 | Centre for Probe Development and Commercialization | Residualizing linkers and uses thereof |
| US10736974B2 (en) | 2014-10-22 | 2020-08-11 | The Johns Hopkins University | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy |
| JP2018506509A (ja) * | 2014-12-09 | 2018-03-08 | アッヴィ・インコーポレイテッド | 細胞透過性Ｂｃｌ−ｘＬ阻害剤との抗体薬物コンジュゲート |
| JP2018515457A (ja) * | 2015-04-21 | 2018-06-14 | アッヴィ・ステムセントルクス・エル・エル・シー | カリケアマイシン構築物および使用方法 |
| TWI714661B (zh) | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
| CN108066772B (zh) * | 2016-11-14 | 2021-07-13 | 中国科学院上海药物研究所 | 靶向tacstd2的抗体与药物偶联体(adc)分子 |
| EP3621658A1 (en) | 2017-05-10 | 2020-03-18 | Sanofi | Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation |
-
2018
- 2018-05-09 EP EP18722557.8A patent/EP3621658A1/en active Pending
- 2018-05-09 BR BR112019023336-9A patent/BR112019023336A2/pt unknown
- 2018-05-09 CA CA3062977A patent/CA3062977A1/en active Pending
- 2018-05-09 MA MA050764A patent/MA50764A/fr unknown
- 2018-05-09 AU AU2018265333A patent/AU2018265333C1/en active Active
- 2018-05-09 KR KR1020197035740A patent/KR102722886B1/ko active Active
- 2018-05-09 MY MYPI2019006354A patent/MY204075A/en unknown
- 2018-05-09 TN TNP/2019/000303A patent/TN2019000303A1/en unknown
- 2018-05-09 UY UY0001037728A patent/UY37728A/es not_active Application Discontinuation
- 2018-05-09 US US15/975,423 patent/US20180369401A1/en not_active Abandoned
- 2018-05-09 TW TW107115718A patent/TWI778059B/zh active
- 2018-05-09 AR ARP180101213A patent/AR111781A1/es not_active Application Discontinuation
- 2018-05-09 WO PCT/EP2018/061989 patent/WO2018206635A1/en not_active Ceased
- 2018-05-09 CN CN201880044816.0A patent/CN110831633A/zh active Pending
- 2018-05-09 US US16/612,090 patent/US20200093934A1/en active Pending
- 2018-05-09 MX MX2019013421A patent/MX2019013421A/es unknown
- 2018-05-09 EA EA201992667A patent/EA201992667A1/ru unknown
- 2018-05-09 JP JP2019561911A patent/JP2020519610A/ja active Pending
-
2019
- 2019-10-29 CO CONC2019/0012108A patent/CO2019012108A2/es unknown
- 2019-10-31 EC ECSENADI201978277A patent/ECSP19078277A/es unknown
- 2019-11-04 US US16/673,367 patent/US11007275B2/en active Active
- 2019-11-05 PH PH12019550230A patent/PH12019550230A1/en unknown
- 2019-11-07 IL IL270507A patent/IL270507B2/en unknown
-
2021
- 2021-03-23 US US17/210,072 patent/US11998611B2/en active Active
-
2022
- 2022-06-30 AU AU2022204711A patent/AU2022204711C1/en active Active
-
2023
- 2023-04-06 JP JP2023061810A patent/JP2023085475A/ja active Pending
-
2024
- 2024-04-10 US US18/631,600 patent/US20250205348A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19078277A (es) | Nuevos ligadores peptídicos y conjugados de criptoficina y su preparación | |
| TR201909093T4 (tr) | Hidroksi içeren FXR (NR1H4) modüle edici bileşikleri. | |
| PY1909256A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| ECSP18034035A (es) | Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico | |
| BR112017005393A2 (pt) | composto de fórmula i, método de preparação de um conjugado de fórmula a, conjugado de fórmula a1, composição compreendendo uma mistura dos compostos de conjugado de anticorpo-fármaco, composição farmacêutica, e uso de um conjugado ou de uma composição | |
| MX2020004804A (es) | Compuestos de modulacion de fxr (nr1h4). | |
| MX2018015443A (es) | Compuestos moduladores de fxr (nr1h4). | |
| CL2018000106A1 (es) | Moléculas de anticuerpo que se unen a cd45 | |
| AR119018A1 (es) | Inhibidores de proteína quinasas dependientes de adn | |
| TR201906401T4 (tr) | Yeni fxr (nr1h4) modüle edici bileşikler. | |
| CL2012003054A1 (es) | Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión. | |
| BRPI1011043B8 (pt) | fenilureias e fenilamidas substituídas como ligantes de receptor de vaniloide, seus usos e seu processo de preparação, e composição farmacêutica | |
| BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
| DOP2010000357A (es) | Derivados de indazoles sustituidos con fenilo o piridinilo | |
| BR112012024822B8 (pt) | Composto, uso de um composto e composição farmacêutica | |
| BR112019005246A2 (pt) | composto com a fórmula i, composto com a fórmula ii, composto com a fórmula iii, composição farmacêutica, método de tratamento de câncer | |
| AR076398A1 (es) | Formulacion | |
| HN2012000217A (es) | Compuestos derivados de amido espirociclicos y sales farmaceuticamente aceptable de los mismos. | |
| AR077972A1 (es) | Anticuerpos contra cdcp1 destinados al tratamiento del cancer | |
| BR112018073490A2 (pt) | 6.7.beta-epóxidos esteroides como intermediários químicos | |
| MX2016001519A (es) | Derivados de 25-oh vitamina d para determinacion de metabolitos de vitamina d. | |
| MX2018002514A (es) | Citotoxinas modificadas y su uso terapeutico. | |
| BR112016011778A2 (pt) | Pirazol fluorofenila, seus usos, e composição farmacêutica | |
| ECSP22021881A (es) | Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso | |
| BR112016002752A8 (pt) | Anticorpo ou seus fragmentos funcionais que pode especificamente se ligar ao her2, polinucleotídeo isolado, combinação dos polinucleotídeos isolados, vetor de expressão, conjugado, conjugado com a fórmula geral ab-(l-u)n, composição farmacêutica e uso do anticorpo ou seus fragmentos funcionais |